LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

Kodu・Aktsiate loetelu・AstraZeneca PLC
Search

AstraZeneca PLC

Avatud

SektorTervishoid

187.25 -1.32

Tugev "osta" hinnang

Hinna uuendus 22. mai 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

186.99

Max

188.07

Põhinäitajad

By Trading Economics

Sissetulek

1.6B

3.9B

Müük

-215M

15B

P/E

Sektori keskmine

27.887

49.701

Aktsiakasum

1.29

Dividenditootlus

1.74

Kasumimarginaal

25.602

Töötajad

96,100

EBITDA

1.1B

5.7B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+15.53% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.74%

2.39%

Järgmine tulemuste avaldamine

27. juuli 2026

Järgmine aktsia dividendi kuupäev (ex-date)

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-3.5B

287B

Eelmine avamishind

188.57

Eelmine sulgemishind

187.25

Uudiste sentiment

By Acuity

35%

65%

93 / 345 Pingereas Healthcare

AstraZeneca PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 16:28 UTC

Tulu

Correction to AstraZeneca Update

DJ

Loe

29. apr 2026, 15:11 UTC

Tulu

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

DJ

Loe

29. apr 2026, 06:31 UTC

Tulu

AstraZeneca Gets Revenue Boost From Cancer Drugs

DJ

Loe

21. mai 2026, 11:06 UTC

Market Talk

AstraZeneca Set for Busy End of Year -- Market Talk

DJ

Loe

13. mai 2026, 12:29 UTC

Market Talk

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

DJ

Loe

13. mai 2026, 11:54 UTC

Market Talk

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

DJ

Loe

1. mai 2026, 09:31 UTC

Market Talk

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

DJ

Loe

29. apr 2026, 10:29 UTC

Market Talk
Tulu

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

DJ

Loe

29. apr 2026, 10:06 UTC

Market Talk
Tulu

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

DJ

Loe

29. apr 2026, 09:53 UTC

Market Talk
Tulu

AstraZeneca Seems in Fine Health -- Market Talk

DJ

Loe

29. apr 2026, 06:05 UTC

Tulu

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

DJ

Loe

29. apr 2026, 06:04 UTC

Tulu

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

DJ

Loe

29. apr 2026, 06:04 UTC

Tulu

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

DJ

Loe

29. apr 2026, 06:03 UTC

Tulu

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

DJ

Loe

29. apr 2026, 06:03 UTC

Tulu

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

DJ

Loe

29. apr 2026, 06:02 UTC

Tulu

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

DJ

Loe

29. apr 2026, 06:01 UTC

Tulu

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

DJ

Loe

29. apr 2026, 06:01 UTC

Tulu

AstraZeneca Backs 2026 View

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Adj EPS $2.58

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Rev $15.29B

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Pretax Pft $3.91B

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Oper Pft $4.25B

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Net Pft $3.08B

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q EPS $1.97

DJ

Loe

27. apr 2026, 10:48 UTC

Market Talk

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

DJ

Loe

10. apr 2026, 11:57 UTC

Market Talk

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

DJ

Loe

10. apr 2026, 10:26 UTC

Market Talk
Tulu

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

DJ

Loe

2. apr 2026, 09:16 UTC

Market Talk

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

DJ

Loe

27. märts 2026, 10:40 UTC

Market Talk

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

DJ

Loe

27. märts 2026, 10:17 UTC

Market Talk

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

AstraZeneca PLC Prognoos

Hinnasiht

By TipRanks

15.53% tõus

12 kuu keskmine prognoos

Keskmine 216.074 USD  15.53%

Kõrge 249.984 USD

Madal 151.872 USD

Põhineb 15 Wall Streeti analüütiku instrumendi AstraZeneca PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

13

Osta

1

Hoia

1

Müü

Põhineb 15 analüütiku instrumendi AstraZeneca PLC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

93 / 345 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,066.82

↑ +2.48%

JNJ

Johnson and Johnson

234.57

↑ +1.33%

ABBV

AbbVie Inc

216.12

↑ +0.45%

UNH

UnitedHealth Group Inc

388.17

↑ +1.5%

AZN.UK

AstraZeneca PLC

13,902

↓-1.08%
help-icon Live chat